evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

14 questions · 14 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 14.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 12 · 85.7%Moderate 0 · 0%High 0 · 0%

Subcutaneous unfractionated heparin vs unfractionated heparin

VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs unfractionated heparin

Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (7 days ‐ 12 months) compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs unfractionated heparin

Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs unfractionated heparin

Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs unfractionated heparin

All‐cause mortality (5 days to 12 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (5 days to 12 months) compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review